2. Search Result
Search Result
Pathways Recommended: Antibody-drug Conjugate/ADC Related
Results for "

antibody fragment

" in MedChemExpress (MCE) Product Catalog:

30

Inhibitors & Agonists

5

Peptides

24

Inhibitory Antibodies

2

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99417
    Abrezekimab

    UCB4144; VR 942

    		 Interleukin Related Inflammation/Immunology
    Abrezekimab (VR 942) contains CDP7766, a humanized, high-affinity, neutralizing, anti-human-IL-13 antibody fragment that binds to IL-13. Abrezekimab prevents binding to the IL-13Rα1 subunit. Abrezekimab can be used in research of asthma .
    Abrezekimab
  • HY-P99437
    Anbenitamab
    1 Publications Verification

    KN-026

    		 EGFR Cancer
    Anbenitamab (KN-026) is a bispecific antibody simultaneously targeting the extracellular domains II and IV of the human HER2. Anbenitamab blocks both ligand-dependent and ligand-independent HER2 signaling pathway. The IgG1 Fc fragment of Anbenitamab binds FcRγIIIa mediates potent antibody dependent cell-mediated cytotoxicity (ADCC) and inhibits tumor cell proliferation. Anbenitamab has the potential for HER2-positive metastatic breast cancer (MBC) research .
    Anbenitamab
  • HY-P99425
    Afelimomab

    MAK 195F

    		 TNF Receptor Infection Inflammation/Immunology
    Afelimomab (MAK 195F) is an anti-tumor necrosis factor F(ab')2 monoclonal antibody fragment. Afelimomab can be used for the research of sepsis .
    Afelimomab
  • HY-P99704
    Licaminlimab

    OCS-02

    		 TNF Receptor Inflammation/Immunology
    Licaminlimab (OCS-02) is a single-chain anti-TNF alpha antibody fragment. TNF alpha is an inflammatory cytokine produced by macrophages and monocytes during inflammation .
    Licaminlimab
  • HY-114531
    Lomifylline

    		Others Others
    Lomifylline is a derivative of Xanthine (HY-W017389). Lomifylline can be used in research of sepsis and septic or endotoxic shock, when combined with an antibody to TNF or a TNF binding fragment .
    Lomifylline
  • HY-P990718
    Cemavafusp

    		PD-1/PD-L1 Inflammation/Immunology
    Cemavafusp is an anti-PD-L1 monoclonal antibody composed of a single chain variable fragment, an antibody heavy chain, and a kappa antibody light chain .
    Cemavafusp
  • HY-P990695
    Lunaxafusp

    		EGFR Inflammation/Immunology
    Lunaxafusp is an anti-ERBB2 scFv-heavy-κ monoclonal antibody composed of a single chain variable fragment, an antibody heavy chain, and a kappa antibody light chain .
    Lunaxafusp
  • HY-P10252
    HIV gp120 (421-438)

    		HIV Inflammation/Immunology
    HIV gp120 421-438 is HIV antigen fragments, that conjugates with keyhole limpet hemocyanin (KLH) and generates specific anti-HIV antibody .
    HIV gp120 (421-438)
  • HY-P10250
    HIV gp120 (308-331)

    		HIV Inflammation/Immunology
    HIV gp120 308-331 is HIV antigen fragments, that conjugates with keyhole limpet hemocyanin (KLH) and generates specific anti-HIV antibody .
    HIV gp120 (308-331)
  • HY-P4042
    Hepatitis B Virus Receptor Binding Fragment

    hepatitis B peptide 4980

    		 HBV Infection Inflammation/Immunology
    Hepatitis B Virus Receptor Binding Fragment (hepatitis B peptide 4980) is a synthetic peptide analog which specifically binds to Hep G2 cells. Hepatitis B Virus Receptor Binding Fragment is a promising immunogen expected to elicit protective antibodies based on the concept of the attachment blockade pathway of virus neutralization .
    Hepatitis B Virus Receptor Binding Fragment
  • HY-P9973
    Brolucizumab

    DLX1008; ESBA 1008; RTH258

    		 VEGFR Cancer
    Brolucizumab (DLX1008) is a single-chain anti-VEGF-A antibody fragment with low picomolar affinity (KD=1.05 pM). Brolucizumab can be used for the research of cancer .
    Brolucizumab
  • HY-P9976A
    Isatuximab (anti-CD38)
    1 Publications Verification

    		 CD38 Cancer
    Isatuximab (anti-CD38) is a monoclonal antibody targeting the transmembrane receptor and extracellular enzyme CD38.Isatuximab induces tumor cell killing via fragment crystallizable (Fc)-dependent or Fc-independent mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC) .
    Isatuximab (anti-CD38)
  • HY-108739
    Idarucizumab

    BI 655075

    		 Thrombin Cardiovascular Disease
    Idarucizumab is a humanized monoclonal antibody fragment. Idarucizumab is first reversal agent for a direct oral anticoagulant (DOAC). Idarucizumab can specifically neutralize the effects of the oral direct thrombin inhibitor in order to restore hemostasis .
    Idarucizumab
  • HY-141663
    2',3'-cGAMP-C2-SH

    		ADC Linker Cancer
    2',3'-cGAMP-C2-SH is a cyclic di-nucleotide (CDN) that can be conjugated to antibodies or antigen-binding fragments targeting specific antigens in the microenvironment of diseased cells or tissue .
    2',3'-cGAMP-C2-SH
  • HY-P99629
    Galegenimab

    FHTR 2163; RG 6147; RO 7171009

    		 Ser/Thr Protease Neurological Disease
    Galegenimab (FHTR 2163; RG 6147; RO 7171009), an anti-High-temperature requirement A1 (HTRA1) antibody fragment. Galegenimab can be used for age-related macular degeneration (AMD) research .
    Galegenimab
  • HY-P990717
    Brenetafusp

    		CD3 Inflammation/Immunology
    Brenetafusp is an anti-CD3E/PRAME monoclonal antibody .
    Brenetafusp
  • HY-P990780
    Zeleciment

    		Transferrin Receptor Inflammation/Immunology
    Zeleciment is an anti-TFRC IgG1κ monoclonal antibody .
    Zeleciment
  • HY-P99313
    Quilizumab

    Anti-Human IGHE Recombinant antibody

    		 Apoptosis Inflammation/Immunology
    Quilizumab (Anti-Human IGHE Recombinant Antibody) is a humanized IgG1κ monoclonal antibody targeting immunoglobulin epsilon (also konwn as: IGHE, IgE). Quilizumab targets the M1-prime fragment of membrane-expressed IGHE/IgE, leading to IGHE/IgE switching and memory B cell depletion. Quilizumab has potential in asthma research .
    Quilizumab
  • HY-P10458
    5-Lipoxygenase blocking peptide

    Human/rat 5-LO (130-149)

    		 Lipoxygenase Others
    5-Lipoxygenase blocking peptide (Human/rat 5-LO 130-149) is a specific sequence fragment of 5-lipoxygenase (5-LOX), which can be utilized to prepare an antibody against 5-LOX .
    5-Lipoxygenase blocking peptide
  • HY-P9953
    Certolizumab pegol

    Certolizumab; CDP870

    		 TNF Receptor Inflammation/Immunology Cancer
    Certolizumab pegol (Certolizumab) is a recombinant, polyethylene glycolylated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumour necrosis factor-α (TNF-α). Certolizumab pegol can be used for rheumatoid arthritis and Crohn disease research .
    Certolizumab pegol
  • HY-P9934
    Abciximab

    C7E3

    		 Integrin Cardiovascular Disease
    Abciximab (C7E3), a chimeric mouse/human monoclonal antibody fragment, is a glycoprotein (GP) IIb/IIIa inhibitor. Abciximab inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein IIb/IIIa, vitronectin and Mac-1 receptors .
    Abciximab
  • HY-P3028
    Ficain

    Ficin

    		 Biochemical Assay Reagents Others Metabolic Disease
    Ficain is an enzyme extract composed of several proteases that can be isolated from Ficus hispida L. and the latex of fig (Ficus carica). Ficain has different specificities in different proportions during fruit ripening. Ficain is widely used in protein hydrolysis, food, production of bioactive peptides and antibody fragments .
    Ficain
  • HY-P99115
    Envafolimab

    ASC 22; KN 035

    		 PD-1/PD-L1 Cancer
    Envafolimab (ASC 22; KN 035) is a recombinant protein of a humanized single-domain anti- PD-L1 antibody. Envafolimab is created by a fusion of the of anti-PD-L1 domain with Fc fragment of human IgG1 antibody. Envafolimab blocks interaction between PD-L1 and PD-1 with an IC50 value of 5.25?nM. Envafolimab has the potential for the research of solid tumors .
    Envafolimab
  • HY-P10628
    β Amyloid (1-14), human

    		Amyloid-β Neurological Disease
    β Amyloid (1-14), human is a peptide fragment of β-amyloid protein (Aβ), which is obtained by hydrolysis of Aβ1-40 peptide by catalytic antibody light chain #7TR. β Amyloid (1-14), human can be used for Alzheimer's disease research .
    β Amyloid (1-14), human
  • HY-P9951A
    Ranibizumab (anti-VEGF)

    RG-6321 (anti-VEGF)

    		 VEGFR Cardiovascular Disease
    Ranibizumab (RG-6321) (anti-VEGF) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165) . Ranibizumab (anti-VEGF) slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research .
    Ranibizumab (anti-VEGF)
  • HY-P99155
    Zalutumumab

    		EGFR Cancer
    Zalutumumab is a high affinity, completely human IgG1 monoclonal antibody targeting EGFR. Zalutumumab binds to domain III of the EGF receptor and acts by blocking the binding of EGF and by sterically interfering with the active conformation of the receptor. Zalutumumab binds with IgG and its Fab fragment with EC50s of 7 and 19 nM, respectively. Zalutumumab can be used for the research of cancer .
    Zalutumumab
  • HY-E70364
    IgdE protease

    		Biochemical Assay Reagents Inflammation/Immunology
    IgdE protease is a cysteine protease, which is initially isolated from Streptococcus agalactiae. IgdE protease digests monoclonal antibodies (mAbs) of the IgG1 type specifically at their upper hinge region, produces Fc/2, hinge peptide dimers, and Fab fragment. IgdE protease can be used in disulfide bonds and free thiol analysis, as it requires no reducing agents for cleavage .
    IgdE protease
  • HY-P99464
    Bectumomab

    IMMU-LL 2

    		 CD22 Cancer
    Bectumomab (IMMU-LL 2) is an humanized IgG2a mAb against human CD22 (antigen). Bectumomab is also an anti-lymphoma antibody fragment. Bectumomab can be used for imaging in combination with technetium 99 (Tc99m LL2 Fab). Moreover, Bectumomab examines in the staging of recurrent or newly diagnosed non-Hodgkin's lymphoma (NHL) and to assess targeting before radioimmunoresearch (RIT) .
    Bectumomab
  • HY-164645
    pan-KRAS-IN-16

    		Ras Cancer
    pan-KRAS-IN-16 (Compound 3344) is an anti-RAS small molecule derived from an intracellular antibody fragment with pan-RAS-effector protein-protein interaction inhibitor properties. pan-KRAS-IN-16 binds to a hydrophobic pocket near to the effector-binding switch regions of RAS. pan-KRAS-IN-16 prevents endogenous RAS-dependent signaling in tumor cell lines .
    pan-KRAS-IN-16
  • HY-129937A
    GNE-987
    1 Publications Verification

    		 PROTACs Epigenetic Reader Domain Cancer
    GNE-987 is a PROTAC connected by ligands for von Hippel-Lindau and BRD4. GNE-987 exhibits picomolar cell BRD4 degradation activity (DC50=0.03 nM for EOL-1 AML cell line). GNE-987 binds equipotently to the BD1 and BD2 bromodomains of BRD4 with low nanomolar affinities (IC50=4.7 and 4.4 nM, respectively). GNE-987 incorporates a potent BET binder/inhibitor, a VHL-binding fragment, and a ten methylene spacer moiety. GNE-987 can be used in PROTAC-Antibody Conjugate (PAC) .
    GNE-987

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: